þ ratio was not significantly associated with incident noncardiac NCDs.
þ lymphocyte ratio. Age differences in the relationship between CD4 þ /CD8 þ ratio and NCDs have not been described.
Design: Observational cohort study.
Methods: We assessed CD4
þ /CD8 þ ratio and incident NCDs (cardiovascular, cancer, liver, and renal diseases) in HIV-infected adults started on antiretroviral therapy between 1998 and 2012. Study inclusion began once patients maintained virologic suppression for 12 months (defined as baseline). We examined age and baseline CD4 þ /CD8 þ ratio and used Cox proportional hazard models to assess baseline CD4 þ /CD8 þ ratio and NCDs.
Results: This study included 2006 patients. Low baseline CD4
þ /CD8 þ ratio was associated with older age, male sex, and low CD4 þ lymphocyte counts. In models adjusting for CD4 þ lymphocyte count, CD4 þ /CD8 þ ratio was inversely associated with age (P < 0.01). Among all patients, 182 had incident NCDs, including 46 with coronary artery disease (CAD) events. CD4 
/CD8
þ ratio was not significantly associated with incident noncardiac NCDs.
þ ratio after 1 year of HIV virologic suppression was independently predictive of decreased CAD risk, particularly among younger adults. Advanced immune senescence may contribute to CAD events in younger HIV patients on antiretroviral therapy.
Introduction
With the success of antiretroviral therapy (ART), the burden of morbidity and mortality among HIV-infected adults is shifting from AIDS-defining illnesses to noncommunicable diseases (NCDs) [1] [2] [3] [4] . In particular, cardiovascular disease, non-AIDS-defining cancers, liver disease, metabolic diseases, and renal diseases occur at high rates and account for a high proportion of deaths in HIV-infected adults [5] [6] [7] . Compared to their uninfected peers, HIV-infected adults experience higher rates of these important NCDs and, in some cases, at younger ages [5, 8, 9] . Understanding the pathophysiology, prevention, and treatment of NCDs have become clinical and research priorities to reduce the excess morbidity that persists among HIV-infected adults on ART.
The underlying immunologic effects of chronic HIV infection have been proposed as one mechanism driving the pathogenesis of NCDs. Research has shown that the features of chronic, treated HIV infection that mirror the immunologic changes observed with aging are also associated with NCD outcomes, including T-lymphocyte activation and replicative senescence, alteration in CD8 þ lymphocyte populations, and elevated systemic measures of innate immune activation [3, 4, 10] . However, studies that have examined the association between CD4 þ lymphocyte counts and NCDs have demonstrated inconsistent results, and a clinically applicable measure of immune senescence as a predictor of NCDs has not yet been identified [11] [12] [13] [14] .
In HIV-uninfected adults, CD4 þ /CD8 þ ratio increases over the lifespan, and inversion of the CD4
þ ratio in the elderly has been associated with risk of frailty and chronic viral infections, such as cytomegalovirus [15] [16] [17] [18] [19] . In HIV-infected adults with virologic suppression, CD4
þ ratio inversely correlates with measures of innate and adaptive immune senescence [20] [21] [22] . HIVinfected adults with NCDs were more likely to have lower CD4
þ ratios than matched controls in recent studies [20, 23] . However, the effect of age on the value of CD4 þ /CD8 þ ratios for identifying patients at risk for incident NCDs has not been evaluated.
The large observational cohort study among HIV-infected adults on ART aimed to examine the relationship between age, CD4 þ
/CD8
þ ratio, and NCDs. We hypothesized that CD4 þ
þ ratio would be correlated with age but remain a predictor of NCD outcomes independent of age.
Methods
The study included adult patients (age 18 years at cohort entry) who received care at the Vanderbilt Comprehensive Care Clinic (VCCC) in Nashville, Tennessee between 1998 and 2012. The VCCC provides specialty HIV care and primary care to HIV-infected adults. Patients are routinely seen in clinic every three to six months. Research staff systematically abstracts demographic, clinical, and laboratory data from the electronic medical record, including NCD diagnoses and dates of onset. All cardiovascular, hepatic, renal, and oncologic NCD diagnoses were individually validated by research and medical staff.
We included patients who enrolled in clinic and started or were maintained on ART between 1 January 1998, and 31 December 2012. Patient follow-up time for the study began at the time of the earliest date of persistent measurement of virologic suppression (HIV-1 RNA <400 copies/ml) after a 12-month period based on at least two laboratory values no more than 12 months apart obtained at the VCCC. This time point was determined to be the baseline for the start of study follow-up time. Additionally, patients were required to have CD4 The outcomes of interest for this study were serious NCDs. These were defined as NCDs with end-organ effects or associated significant morbidity or risk of mortality, including cardiovascular disease (CVD) events, non-AIDS-defining cancers, cirrhosis, advanced chronic kidney disease, and diabetes. CVD included coronary artery disease (CAD) events (myocardial infarctions, coronary artery atherosclerosis, or ischemic cardiomyopathy), cerebrovascular events, and peripheral vascular disease as recorded by healthcare providers in the medical record. Oncologic NCDs included invasive malignancies, excluding squamous and basal cell skin cancers and AIDSdefining cancers (Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer). Hepatic NCDs included cirrhosis because of any cause, as documented by healthcare providers in the medical record. Renal NCDs included incident stage IV (estimated glomerular filtration rate 15-30 ml/min) or stage V (estimated glomerular filtration rate <15 ml/min) chronic kidney disease as documented in the medical record by healthcare providers. Incident diabetes was defined as new diagnoses documented in the medical record by healthcare providers.
The primary predictor of interest was CD4 þ /CD8 þ ratio after the first 12 months of virologic suppression (baseline), defined as CD4 þ lymphocyte count (cells/ml) divided by CD8 þ lymphocyte count (cells/ml). As CD4 þ lymphocyte counts are highly dependent upon HIV-1 RNA, we selected the value after the first year of virologic suppression as a consistent measure of adaptive immune status independent of HIV-1 replication [24] . Baseline CD4 þ /CD8 þ ratio was categorized by approximate tertiles into low (<0.40), middle (0.40-0.69), and high (0.70). Previous studies have observed CD4
þ ratio <0.4 as predictive of NCD outcomes in HIV-infected adults on ART [20, 23] . Patient demographic and clinical characteristics were compared between those with low and high baseline CD4 þ /CD8 þ ratio using Wilcoxon rank sum and chi-square test for continuous and categorical variables, respectively.
We explored the association between age and CD4
þ ratio using linear regression models. We examined the relationship of baseline CD4 þ /CD8
þ ratio and age using data from all participants. Age was fit using restricted cubic splines with the number of knots determined by the Akaike information criterion. An interaction term for CD4 þ lymphocyte counts and age was included. The results of the linear regression models for CD4
þ ratio outcomes by age were graphed and stratified by CD4 þ lymphocyte count categories.
We next examined change in CD4 þ /CD8 þ ratio over time among patients with persistent measurements of virologic suppression; follow-up was censored at the first occurrence of an HIV-1 RNA level 400 copies/ml or more or gap in HIV-1 RNA measurements of more than 6 months. The association between age and change in CD4 þ /CD8 þ ratio after 3 years of virologic suppression from baseline was examined using linear regression with restricted cubic splines, including adjustment for and examination of effect modification by baseline CD4 þ lymphocyte count.
Lastly, we examined the risk of NCDs predicted by baseline CD4 þ /CD8 þ ratio. We compared the baseline CD4 þ /CD8 þ ratio between patients with no NCD events during study follow-up to those patients with cardiovascular, oncologic, hepatic or renal NCDs, or incident diabetes diagnosis using the Wilcoxon rank sum test. We calculated the cumulative incidence of each NCD category and a composite NCD outcome by baseline CD4 þ /CD8 þ ratio tertiles.
To examine the relationship of CD4 þ /CD8 þ ratio and NCDs over time, we performed Cox proportional hazard models for each NCD category and a composite outcome for any NCD event. For the composite NCD model, patients were censored after their first NCD event. For the models for each NCD category, patients were censored after their first NCD event of that category. Variables for inclusion in adjusted models were selected a priori based upon pathophysiology (including age, sex, and CD4
þ lymphocyte count as priority covariates) and number of events (degrees of freedom). Age was included using restricted cubic splines (three knots). Adjusted models were repeated with inclusion of an interaction term for age and CD4 þ /CD8 þ ratio and, when feasible, stratifying by age to assess for effect modification.
As a sensitivity analysis, all statistical studies were repeated excluding those patients with HIV-1 RNA less than 400 copies/ml at clinic entry as their duration of virologic suppression was unknown and may affect their CD4 þ / CD8 þ ratio. 
Results
From 1998 to 2012, 2245 ART-naïve patients were enrolled into care at the clinic, started or maintained on ART, and had consistent measurements of suppressed HIV-1 RNA (<400 copies/ml) for at least 12 months. Study follow-up began after the first 12 months of sustained virologic suppression (i.e., baseline). Twohundred and twenty-one patients (10%) had missing CD4 þ or CD8 þ lymphocyte count values within 6 months of the baseline date and were excluded, leaving 2006 patients included in this study. These patients contributed a total of 8762 person-years of follow-up.
At baseline, the median CD4
þ ratio for all participants was 0.57 (interquartile range: 0.36-0.85).
Patient demographic and clinical characteristics by baseline CD4
þ /CD8 þ ratio are shown in Table 1 . Compared to patients with higher CD4
þ ratio (0.7), those in the lowest tertile (ratio <0.4) were older, more likely to be male, had lower CD4 þ lymphocyte nadir and CD4 þ lymphocyte count values at baseline, and were more likely to have HIV-1 RNA less than 400 copies/ml but detectable at baseline. They were less likely to have virologic suppression at clinic entry. There were slightly longer duration of ART at baseline and longer follow-up time after baseline among patients with the lowest vs. highest CD4 þ /CD8 þ ratios but these differences did not reach statistical significance. Figure 1a shows the baseline CD4 þ /CD8 þ ratio by age, including results stratified by CD4 þ lymphocyte count. Baseline CD4 þ /CD8 þ ratio was inversely associated with age (likelihood ratio test, P < 0.001). The association between CD4 þ /CD8 þ ratio and age did not statistically differ by CD4 þ lymphocyte count (test of interaction P ¼ 0.80).
We next examined patients with consistent measurements of virologic suppression (HIV-1 RNA <400 copies/ml) þ ratio (median ratio ¼ 0.37, interquartile range 0.27-0.63) (not shown in Fig. 2 ). There were no statistically significant differences in baseline CD4
þ ratio values for those patients with subsequent cancer, diabetes, cirrhosis, or renal outcomes compared to those without any NCD events. Similarly, cumulative incidence of CVD outcomes was highest among patients with the lowest CD4 þ /CD8 þ ratios (<0.4) compared to those with higher CD4 þ /CD8 þ ratios at baseline (Fig. 3) . In contrast, patients with lower CD4 þ /CD8 þ ratio at baseline did not have a higher incidence of diabetes or cirrhosis compared to patients with higher ratios.
We examined CD4
þ /CD8 þ ratio and age on risk of NCDs in Cox proportional hazard models ( As a sensitivity analysis, we repeated all statistical studies excluding the 365 patients with HIV-1 RNA less than 400 copies/ml at the time of clinic entry. The results of the association of age and CD4 þ /CD8 þ ratio as well as CD4 þ /CD8 þ ratio and the NCD outcomes were unaffected (data not shown).
Discussion
In this observational cohort study, we found that low CD4 þ /CD8 þ ratio after the first year of virologic suppression in HIV-infected adults was independently associated with serious CAD outcomes. This association was strongest among patients aged less than 50 years, though analyses were limited by small numbers of events in older patients. There was no statistical interaction between CD4 þ /CD8 þ ratio and age on risk of any NCDs. In the setting of successful ART and regardless of CD4
þ lymphocyte values, CD4 þ /CD8 þ ratio was highly associated with age, supporting the observation that CD4 þ /CD8 þ ratio may be a marker of aging-associated immune senescence in HIV-infected adults.
In our study, low CD4 þ /CD8 þ was strongly associated with older age in HIV-infected adults on stable ART. Our study is novel in its exploration of the relationship þ /CD8 þ ratio among patients without any NCD events. between age and CD4
þ ratio as prior studies have largely used case-control designs that have matched on age. Chronic HIV infection has been observed to cause immunologic changes similar to those observed in natural aging, including decreased naive T-lymphocyte populations, increased T-lymphocyte activation, T-lymphocyte replicative senescence, and increased immune activation, among others [25] [26] [27] [28] [29] [30] . Previous studies have demonstrated that CD4 þ
/CD8
þ ratio correlates with a number of these adaptive immune senescence changes in HIV-infected adults on ART [20, 21, 31] . In older HIV-infected adults on ART, the immune senescent effects of HIV and aging are often additive [32] [33] [34] . Furthermore, CD4
þ /CD8 þ ratio also inversely correlates with measures of innate immune activation including soluble CD14, C-reactive protein, and interleukin 6 in HIV-infected adults on ART [20] . In aging HIVuninfected adults, CD4 þ /CD8 þ ratio increases over the lifespan and inversion of the ratio is associated with immunologic effects of chronic viral infections, particularly CMV [19, 35] . The strong association between age and CD4 þ /CD8 þ ratio in our study of HIV-infected adults on ART supports the conclusion that CD4
þ ratio reflects the cumulative immune senescent effects of chronic viral infections, such as HIV or herpes viruses. Our study found a trend toward reduced CD4 þ / CD8 þ improvement over time in older adults, after adjustment for CD4 þ lymphocyte count. Formal testing of interaction terms for age and CD4 þ lymphocyte count were not statistically significant. Further study of the effects of age and CD4 þ lymphocyte count on CD4
þ ratio over time is needed. The cohort study demonstrated an association of CD4
þ ratio and CAD outcomes. In adjusted models, higher CD4 þ /CD8 þ ratio was significantly associated with decreased risk incident CAD events. CD4 þ /CD8 þ ratio has recently been observed in a number of cohorts to not only be associated with immunologic measures of senescence but atherosclerosis in HIV-infected adults [20, 23, 36, 37] . In particular, clinical studies that have used computed tomography of coronary angiography or carotid artery intima-media thickness have found low CD4
þ ratio associated with measures of subclinical atherosclerosis [36, 37] . Although markers of systemic inflammation and monocyte activation have been strongly associated with CVD outcomes in HIV-infected adults, T-lymphocyte activation and senescence has also been linked to measures of carotid artery stiffness in HIVinfected adults [4, 10, 38, 39] . The hypothesized immunologic mechanisms of CVD in HIV-infected adults are multiple, including activation of endothelial cells, immune activation, and alteration in lipid function [40] . Although some studies have shown either CD4 þ or CD8 þ lymphocyte measures are independent predictors of CVD outcomes, others have found no association [13, [41] [42] [43] [44] [45] . Of note, CD4 þ /CD8 þ ratio has been observed to show less intraindividual variability over time compared to either CD4 þ or CD8 þ lymphocyte counts [20] . Given its association with immune senescence and routine measurement in HIV clinical care, CD4
þ /CD8 þ ratio may serve as important biomarker for CVD in treated HIV-infected adults. Furthermore, in our study, CD4
þ ratio was most strongly associated with CAD in patients less than 50 years of age and its association was attenuated when peripheral vascular disease and cerebrovascular disease (diseases more prevalent at older ages) were added in CVD models. This observation suggests that the utility of CD4
þ ratio as a potential clinical biomarker for CVD risk and as a measure of adaptive immune senescence may differ across the lifespan of the HIV-infected adult on ART.
Finally, our study unexpectedly found a significant association between depression and risk of CVD and diabetes, independent of age, sex, race, CD4 þ /CD8 þ ratio, and CD4 þ cell count. Depression has been observed to increase the risk of CVD in HIV-uninfected populations and is of growing interest in HIV research as a risk factor for CVD outcomes [46] [47] [48] . The results of our study add to this growing body of literature and further study of depression as a potentially modifiable risk factor for CVD is needed.
The cohort study has some limitations. We used the CD4 þ /CD8 þ ratio after 1 year of virologic suppression as our primary predictor of interest rather than timeupdated values in order to limit the effect of episodic HIV viremia [24] . The immune response following the first few years of ART has been shown in other studies to be a reliable reflection of changes over time during ART and has been associated with NCD outcomes [4, 49] . However, we are unable to draw conclusions about the role of time-varying changes in CD4 þ
þ ratio and risk of future NCDs based upon results of our study. Our study is also limited by its observational design. While we controlled for the confounders of CD4 þ lymphocyte count, age, and sex in our multivariate models assessing CD4 þ /CD8 þ ratio and NCD outcomes, we cannot exclude that unmeasured confounders may have affected our results. For example, adaptive immune senescence due to CMV infection has been associated with CVD outcomes [18, 50] . As CMV antibody titers are not CD4 R /CD8 R ratio, age, and NCDs Castilho et al. 905 þ ratio, in HIV-infected adults.
In this cohort analysis of HIV-infected adults on ART and NCD outcomes, we found CD4 þ /CD8 þ ratio to be an important measure of aging-associated immune senescence and a significant, independent predictor of CAD events. Further studies to examine its role as clinical biomarker of CVD outcomes are needed in prospective studies and in larger cohorts. Additionally, the role of variation in CD4 þ
þ ratio over time and the underlying mechanisms associated with premature immune senescence in younger HIV-infected adults warrant further exploration. As the causes of morbidity and mortality in HIV-infected adults increasingly shift to those of NCDs, the need for further understanding and prevention of these outcomes grows more urgent.
